The Essentials
- What supportive infusion care is: Supportive infusion care includes medications and fluids given alongside cancer treatment to manage side effects, protect organs, prevent complications, and help the body recover between cycles. It includes anti-nausea infusions, hydration, bone-modifying agents, PPIs, iron, growth factor support and electrolyte replacement.
Why it matters for breast and lung cancer: Breast and lung cancer are the two most common cancers in Saudi Arabia, and both are treated with intensive regimens that carry a heavy side effect load. Strong supportive care reduces dose delays, hospital admissions, and unplanned visits, and protects quality of life throughout a treatment course that can span months or years.
Where IV One fits in: IV One Infusion Centre administers supportive infusions on referral from your treating oncologist. We do not change your treatment plan; we deliver the supportive care your oncology team has prescribed, in a calm outpatient setting that fits around your treatment cycles.
What Supportive Infusion Care Means in Oncology
Supportive infusion care, sometimes called supportive oncology or supportive therapy, is a part of cancer treatment that does not target the tumor directly. It manages side effects, protects organs, prevents complications and supports recovery so that the primary regimen can keep working.
The European Society for Medical Oncology and the Multinational Association of Supportive Care in Cancer both classify supportive care as an essential component of modern cancer treatment, not an optional add-on. Strong supportive care has been shown to reduce dose reductions, hospital admissions and treatment interruptions, all of which affect outcomes.
Supportive infusions are usually delivered either on the same day as the primary regimen, in the days between cycles, or as a standalone visit when a specific complication needs attention. Most are short, typically 15 minutes to 2 hours per session.
Why Breast and Lung Cancer Need Strong Supportive Care
According to the Saudi Cancer Registry, breast cancer is the most commonly diagnosed cancer in women in the Kingdom, and lung cancer is among the leading causes of cancer death in both men and women. Both are treated with regimens that combine chemotherapy, targeted therapy or immunotherapy, and both carry side effect loads that supportive infusion care is specifically designed to manage.
High prevalence in Saudi Arabia
Public investment in screening, early detection and access to modern cancer treatments under Vision 2030 has meant more patients are diagnosed earlier and treated with curative or life-extending intent. This, in turn, raises the bar for supportive care, because patients are living longer with active treatment.
Treatment intensity
Breast cancer regimens often combine chemotherapy, HER2 targeted therapy, Hormonal therapy and bone-strengthening infusions across many months. Lung cancer regimens increasingly combine chemotherapy with immunotherapy and targeted agents. Both place sustained physical demand on the body.
Treatment duration
Some breast cancer patients receive trastuzumab maintenance for a full year while others received hormonal therapy for 5 years. Many lung cancer patients receive immunotherapy for one to two years. Across that timeline, supportive infusions are what keep the primary regimen tolerable.
Common Supportive Infusions for Breast Cancer Patients
The supportive infusions most prescribed for breast cancer patients in oncology clinics fall into six categories.
Anti-nausea infusions
Chemotherapy regimens used in breast cancer, particularly anthracyclines and taxanes, are highly emetogenic. Anti-nausea infusions such as 5HT3 antagonists, NK1 receptor antagonists and corticosteroids are routinely prescribed to prevent nausea and vomiting in line with ASCO and MASCC antiemetic guidelines.
Hydration support
Many chemotherapy and supportive agents place strain on the kidneys. Scheduled IV hydration before, during and after a cycle helps protect renal function and reduces fatigue.
Bone-modifying agents
Patients with bone metastases or treatment-induced bone loss are often prescribed zoledronic acid or denosumab. These infusions strengthen bones, reduce skeletal complications and lower fracture risk across a long treatment course.
Iron and Anemia Support
Chemotherapy-induced anemia is common, and IV iron infusions are now the preferred option over oral iron because of faster correction, good response and fewer gastrointestinal side effects.
Growth factor support
Granulocyte colony-stimulating factor (G-CSF) injections, such as filgrastim or peg filgrastim, are prescribed as prophylaxis to reduce the risk of febrile neutropenia in higher-risk breast cancer regimens.
Electrolyte replacement
Magnesium, calcium and potassium replacement infusions are common when chemotherapy or targeted agents disturb electrolyte balance.
Common Supportive Infusions for Lung Cancer Patients
Lung cancer supportive care overlaps significantly with breast cancer but has some specific differences in emphasis.
Anti-nausea infusions
Platinum based chemotherapy used in lung cancer, particularly cisplatin, is one of the most emetogenic regimens in oncology. Strong multi-agent antiemetic protocols are essential.
Hydration support
Cisplatin requires aggressive pre and post hydration to protect the kidneys. This is one of the most common supportive infusions for lung cancer patients.
Bone modifying agents
Bone metastases are common in advanced lung cancer. Zoledronic acid or denosumab infusions reduce skeletal events such as fractures and spinal cord compression.
Anemia management
Iron infusions, transfusions and selected use of erythropoiesis stimulating agents are used to manage cancer related and treatment related anemia.
Growth factor support
G-CSF support is used to prevent neutropenia in higher risk chemotherapy and combination immunotherapy regimens.
Electrolyte replacement
Magnesium loss is particularly common with cisplatin-based regimens and with some targeted agents used in lung cancer. Magnesium and other electrolyte infusions are often required between cycles.
A Practical Reference Table: Supportive Infusions in Breast and Lung Cancer
| Supportive Infusion | Purpose | Typical Session Length | When Most Commonly Used |
| Anti-nausea (5HT3, NK1, dopamine (D2) receptor antagonist, steroid) | Prevent and treat chemotherapy related nausea and vomiting | 15 to 60 minutes | Same day as chemotherapy and 1 to 3 days after |
| IV hydration (Dextrose, NS) | Protect kidneys, reduce fatigue, support recovery | 30 to 120 minutes | Around cisplatin, taxanes and high dose chemotherapy |
| Bone modifying agents | Strengthening bone, prevent skeletal complications | 15 to 30 minutes | Every 4 to 12 weeks for bone metastases or treatment induced bone loss |
| IV iron | Correct chemotherapy induced anemia | 15 to 60 minutes | When hemoglobin drops below threshold less than 10 |
| Growth factor support (G CSF) | Prevent febrile neutropenia | 5 to 15 minutes (subcutaneous in most cases) | After higher risk chemotherapy cycles |
| Electrolyte replacement | Correct magnesium, calcium, potassium loss | 30 to 90 minutes | Between cycles or as needed based on bloods |
This is not a treatment plan. It is a reference for what supportive infusion care looks like in practice. Your oncologist decides which of these you need, when and at what dose.
How Strong Supportive Care Improves Outcomes
Supportive infusion care is not optional comfort care. Multiple guidelines from ASCO, ESMO and the American Cancer Society place it at the core of high-quality cancer treatment.
Fewer dose delays and dose reductions
Side effects are the most common reason that chemotherapy doses are delayed or reduced. Strong supportive care keeps patients on schedule and at full dose.
Lower hospital admission rates
Febrile neutropenia, severe nausea and vomiting, dehydration and electrolyte imbalances are leading causes of unplanned hospital admissions during cancer treatment. Supportive infusion care addresses each of these directly.
Better treatment adherence
Patients who feel reasonably well between cycles are more likely to complete their full treatment course, which has a measurable impact on long-term outcomes.
Improved quality of life
A several months or years treatment course is a life event for the whole family. Supportive care is what keeps that period manageable.
Breast and Lung Cancer Care in Saudi Arabia
Saudi Arabia has expanded oncology infrastructure significantly under Vision 2030. National screening programs for breast cancer have improved early detection rates, and access to modern lung cancer regimens including immunotherapy and biomarker driven targeted therapy is now standard at tertiary cancer centers.
Tertiary care and the rise of ambulatory delivery
Riyadh’s leading cancer centers deliver world class primary treatment, but oncology day care units are operating at high capacity. The shift towards delivering supportive infusions in dedicated outpatient settings is helping ease that pressure and is giving patients shorter waits, more privacy and easier scheduling around their treatment cycles.
The role of referral-based outpatient infusion
Outpatient infusion centers like IV One do not replace the hospital relationship. They complement it, by administering the supportive infusions the hospital oncologist has prescribed, on a schedule that works around the rest of the treatment plan.
How IV One Supports Breast and Lung Cancer Patients
IV One Infusion Center is Saudi Arabia’s first dedicated medical intravenous therapy center, Riyadh. We do not diagnose cancer, and we do not design your treatment plan, that work belongs to your treating oncologist. What we do is administer the supportive infusions and treatments they have prescribed, in a calm, private outpatient setting that fits around your treatment cycles. Meet our clinical team before you commit.
A faithful extension of your oncologist’s plan
We administer your prescribed regimen, supportive or primary, exactly as ordered. Every preparation is reviewed by an oncology trained pharmacist, and every infusion is delivered by a chemotherapy certified nurse.
Licensed and accredited
IV One holds a Saudi Ministry of Health license since 2024 and Council of Health Insurance accreditation, with full Saudi FDA pharmacy oversight.
Designed around long treatment courses
Breast and lung cancer treatment can stretch across many months or years. Our private suites, family seating, calm lighting and consistent care team are designed for that timeline.
Scheduled around your cycles
We coordinate supportive infusions to fit alongside your hospital treatment days, not on top of them. Less travel, fewer separate visits, more time at home.
Wider scope under one roof
We administer infusion therapy across oncology and many other chronic conditions. See the full list on our conditions we treat page.
Frequently Asked Questions
What is the difference between primary cancer treatment and supportive infusion care?
Can supportive infusions be given on the same day as chemotherapy?
Do I need a referral for supportive infusion care at IV One?
Are supportive infusions safe in an outpatient setting?
Will supportive infusion care help my fatigue?
Can my family join me during supportive infusion sessions?
How long does a supportive infusion session take?
Can lung cancer patients on cisplatin receive their hydration outside the hospital?
Yes, when prescribed by your oncologist and clinically appropriate. Hydration regimens for cisplatin are commonly delivered as scheduled outpatient infusions.
For more answers, visit our IV therapy FAQs.
Key Takeaways
Supportive infusion care is a part of cancer treatment that protects the body, manages side effects and keeps the primary regimen on schedule. It is essential, not optional.
Breast and lung cancer are the two most prevalent cancers in Saudi Arabia, and both are treated with intensive several months or years regimens that depend heavily on strong supportive care.
The most common supportive infusions for these patients include anti-nausea agents, PPIs, hydration, bone modifying agents, iron, growth factor support and electrolyte replacement.
Strong supportive care reduces dose delays, lowers unplanned hospital admissions, improves treatment adherence and protects quality of life across the treatment course.
IV One Infusion Center delivers oncology infusion therapy, including supportive infusion care, on referral from your treating oncologist, in a calm and accredited outpatient setting.
Speak to IV One
If you or someone in your family is receiving treatment for breast or lung cancer and your oncologist has prescribed supportive infusions, our team can administer them for you in Riyadh. We will coordinate directly with your oncologist, fit sessions around your existing treatment days, and make sure your treatment course is supported from start to finish.
Get in touch with the IV One team to start the conversation.
Sources and references: American Cancer Society, American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Multinational Association of Supportive Care in Cancer (MASCC), Saudi Cancer Registry, Saudi Food and Drug Authority (SFDA), Saudi Ministry of Health (MOH), Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI), Council of Health Insurance (CHI).